Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.

导出 OA

翻译打印收藏纠错

作者： Zi-Xuan,Li ^[1] ; Lian-Yue,Qu ^[2] ; Hi,Wen ^[3] ; Hong-Shan,Zhong ^[4] ; Ke,Xu ^[4] ; Xue-Shan,Qiu ^[5] ; En-Hua,Wang ^[5]

作者单位： Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology, The First Affiliated Hospital of China Medical University Shenyang 110001, P. R. China ; Department of Pathology, The First Affiliated Hospital of China Medical University and College of Basic Medical Sciences, China Medical University Shenyang 110001, P. R. China. ^[1] Department of Pharmacy, The First Affiliated Hospital of China Medical University Shenyang 110001, P. R. China. ^[2] Department of Pathology, The First Affiliated Hospital of China Medical University and College of Basic Medical Sciences, China Medical University Shenyang 110001, P. R. China ; Shiyan Taihe Hospital Shiyan 442000, P. R. China. ^[3] Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology, The First Affiliated Hospital of China Medical University Shenyang 110001, P. R. China. ^[4] Department of Pathology, The First Affiliated Hospital of China Medical University and College of Basic Medical Sciences, China Medical University Shenyang 110001, P. R. China. ^[5]

关键词 EGFR signaling Mig-6 NSCLC gefitinib resistance